TBICheck: A Rapid Test to Rule-Out CT scans in Mild Traumatic Brain Injury Patients
Main Article Content
Abstract
Introduction: The TBICheckTM Rapid test is an immunochromatographic rapid test capable of assisting in the triage of patients with mild Traumatic Brain Injury suspected of brain lesions. It quantitatively determines heart-type Fatty Acid Binding Protein (H-FABP) levels in whole blood, serum, or plasma. The aim of the present study was to evaluate its technical performance and test it in two different cohorts of mTBI patients as a potential diagnostic tool for detecting brain lesions in patients with mTBI.
Material and methods: Description of the assay: Linearity and low limit of quantification of TBICheckTM lateral flow assay were determined using serial dilution of standardized samples. Results were read using the TBICheckTM Reader, a mobile photometric immunoassay analyzer based on reflectance measurements to capture the optical density. Obtained results were compared to classical ELISA assays, Meso Scale Diagnostics. Patient cohorts: Two different cohorts of adult mTBI patients were included: a retrospective one including 82 patients and a prospective one including 65 patients. Values of H-FABP area under the curve, specificity, sensitivity were calculated.
Results: The H-FABP dose response fitted a linear regression within the range of 0.5-25 ng/mL. LLOQ in blood was 0.5 ng/mL. High Spearman correlation was found (ρ=0.933, p<0.001) when MSD ELISA and TBICheckTM concentrations were compared.
In the retrospective cohort, when the clinical sensitivity was set at 100%, a specificity value of 32.9% was obtained. In the prospective cohort, the SP value raised to 66.1% with 100% SE, meaning that 6 out of 10 patients might be discharged on the basis of their serum H-FABP concentration at hospital admission.
Conclusions: The quantification of H-FABP by using the TBICheckTM Rapid test on adult mTBI patients may allow to rule out the need of a CT-scan reducing the radiation exposure and avoiding the long waiting times in emergency units. It may lead to savings in hospital resources and assists medical doctors to provide the most appropriate treatment to the patients.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Peeters W, van den Brande R, Polinder S, et al. Epidemiology of traumatic brain injury in Europe. Acta Neurochir (Wien). 2015;157(10):1683-1696.
3. Majdan M, Plancikova D, Brazinova A, et al. Epidemiology of traumatic brain injuries in Europe: a cross-sectional analysis. Lancet Public Health. 2016;1(2):e76-e83.
4. Lefevre-Dognin C, Cogné M, Perdrieau V, Granger A, Heslot C, Azouvi P. Definition and epidemiology of mild traumatic brain injury. Neurochirurgie. 2021;67(3):218-221.
5. Sultan HY, Boyle A, Pereira M, Antoun N, Maimaris C. Application of the Canadian CT head rules in managing minor head injuries in a UK emergency department: implications for the implementation of the NICE guidelines. Emerg Med J. 2004;21(4):420-425.
6. Levine Z. Mild traumatic brain injury: part 1: determining the need to scan. Can Fam Physician. 2010;56(4):346-349.
7. Ruff RM, Iverson GL, Barth JT, Bush SS, Broshek DK. Recommendations for diagnosing a mild traumatic brain injury: a National Academy of Neuropsychology education paper. Arch Clin Neuropsychol. 2009;24(1):3-10.
8. Shobeirian F, Ghomi Z, Soleimani R, Mirshahi R, Sanei Taheri M. Overuse of brain CT scan for evaluating mild head trauma in adults. Emergency Radiology. 2021;28(2):251-257.
9. Melnick ER, Szlezak CM, Bentley SK, Dziura JD, Kotlyar S, Post LA. CT overuse for mild traumatic brain injury. Jt Comm J Qual Patient Saf. 2012;38(11):483-489.
10. Al Omran B, Patil JD, Anala A, et al. Prevalence of Computed Tomography Overuse for Mild Head Injury in Adults. Cureus. 2023;15(2):e35551.
11. Arbabi M, Sheldon R, Bahadoran P, Smith JG, Poole N, Agrawal N. Treatment outcomes in mild traumatic brain injury: a systematic review of randomized controlled trials. Brain Inj. 2020;34(9):1139-1149.
12. Jović M, Prim D, Saini E, Pfeifer ME. Towards a Point-of-Care (POC) Diagnostic Platform for the Multiplex Electrochemiluminescent (ECL) Sensing of Mild Traumatic Brain Injury (mTBI) Biomarkers. Biosensors (Basel). 2022;12(3).
13. Gozal YM, Carroll CP, Krueger BM, Khoury J, Andaluz NO. Point-of-care testing in the acute management of traumatic brain injury: Identifying the coagulopathic patient. Surg Neurol Int. 2017;8:48.
14. Pankratova N, Jović M, Pfeifer ME. Electrochemical sensing of blood proteins for mild traumatic brain injury (mTBI) diagnostics and prognostics: towards a point-of-care application. RSC Advances. 2021;11(28):17301-17319.
15. Steinmüller JB, Lynnerup NM, Steinmetz J, Riis JJ, Doering P. Implementation of the S100 Calcium-Binding Protein B Biomarker in a Clinical Setting: A Retrospective Study of Benefits, Safety, and Effectiveness. Neurotrauma Rep. 2022;3(1):447-455.
16. Faisal M, Vedin T, Edelhamre M, Forberg JL. Diagnostic performance of biomarker S100B and guideline adherence in routine care of mild head trauma. Scand J Trauma Resusc Emerg Med. 2023;31(1):3.
17. Posti JP, Tenovuo O. Blood-based biomarkers and traumatic brain injury-A clinical perspective. Acta Neurol Scand. 2022;146(4):389-399.
18. Ahmadi S, Roshdi Dizaji S, Babahajian A, Alizadeh M, Sarveazad A, Yousefifard M. Serum Glial Fibrillary Acidic Protein in Detecting Intracranial Injuries Following Minor Head Trauma; a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2023;11(1):e9.
19. Posti JP, Takala RSK, Lagerstedt L, et al. Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury. J Neurotrauma. 2019;36(14):2178-2189.
20. Sharma R, Rosenberg A, Bennett ER, Laskowitz DT, Acheson SK. A blood-based biomarker panel to risk-stratify mild traumatic brain injury. PLoS One. 2017;12(3):e0173798.
21. Wunderlich MT, Hanhoff T, Goertler M, et al. Release of brain–type and heart–type fatty acid–binding proteins in serum after acute ischaemic stroke. Journal of Neurology. 2005;252(6):718-724.
22. Koivikko P, Posti JP, Mohammadian M, et al. Potential of heart fatty-acid binding protein, neurofilament light, interleukin-10 and S100 calcium-binding protein B in the acute diagnostics and severity assessment of traumatic brain injury. Emerg Med J. 2022;39(3):206-212.
23. Lagerstedt L, Egea-Guerrero JJ, Bustamante A, et al. H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury. PLoS One. 2017;12(4):e0175572.
24. Lagerstedt L, Azurmendi L, Tenovuo O, et al. Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury. Frontiers in Neurology. 2020;11(376).
25. Kankaanpää M, Raitakari M, Muukkonen L, et al. Use of point-of-care testing and early assessment model reduces length of stay for ambulatory patients in an emergency department. Scand J Trauma Resusc Emerg Med. 2016;24(1):125.
26. Scalise D. Poised for growth. Point-of-care testing. Hosp Health Netw. 2006;80(9):77-83.
27. Arciniegas DB, Anderson CA, Topkoff J, McAllister TW. Mild traumatic brain injury: a neuropsychiatric approach to diagnosis, evaluation, and treatment. Neuropsychiatric Disease and Treatment. 2005;1(4):311-327.
28. Katz DI, Cohen SI, Alexander MP. Mild traumatic brain injury. Handb Clin Neurol. 2015;127:131-156.
29. van Gils A, Stone J, Welch K, et al. Management of mild traumatic brain injury. Pract Neurol. 2020;20(3):213-221.
30. James Kennedy DL, Ann Van den Bruel, Christopher P. Price, Matthew Thompson, Carl , Heneghan AP. Point-of-care testing for heart-type Fatty Acid Binding Protein. Primary Care Diagnostic Horizon Scanning Centre Oxford. 2014.
31. Bruins Slot MH, Rutten FH, van der Heijden GJ, et al. Diagnostic value of a heart-type fatty acid-binding protein (H-FABP) bedside test in suspected acute coronary syndrome in primary care. Int J Cardiol. 2013;168(2):1485-1489.
32. Ecollan P, Collet JP, Boon G, et al. Pre-hospital detection of acute myocardial infarction with ultra-rapid human fatty acid-binding protein (H-FABP) immunoassay. Int J Cardiol. 2007;119(3):349-354.
33. Figiel Ł, Kasprzak JD, Peruga J, et al. Heart-type fatty acid binding protein--a reliable marker of myocardial necrosis in a heterogeneous group of patients with acute coronary syndrome without persistent ST elevation. Kardiol Pol. 2008;66(3):253-259, discussion 260-251.
34. Alhashemi JA. Diagnostic accuracy of a bedside qualitative immunochromatographic test for acute myocardial infarction. Am J Emerg Med. 2006;24(2):149-155.
35. Hisamuddin Nar N, Suhailan MA. Evaluation of the diagnostic indices and clinical utility of qualitative cardiodetect® test kit in diagnosis of ami within 12 hours of onset of chest pain in the emergency department. Int J Emerg Med. 2011;4:67.
36. Lagerstedt L, Egea-Guerrero JJ, Bustamante A, et al. Combining H-FABP and GFAP increases the capacity to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury. PLoS One. 2018;13(7):e0200394.